FDA Approves First Oral PCSK9 Inhibitor

• by Kathryn Wighton

• July 16, 2026

Oral Aleniglipron Reduced Weight at 36 Weeks

In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.

• by Kathryn Wighton

• July 16, 2026

• 6 min

GLP-1 RAs Associated With Small ION Risk Increase

In an observational US target trial emulation, glucagon-like peptide-1 receptor agonist initiation was associated with about 3 to 4 more ischemic optic neuropathy cases per 10,000 patients over 18 months than two comparator drug classes.

• by Andrea Surnit

• July 13, 2026

• 5 min

Association between the fibrosis-4 index and carotid atherosclerosis in Chinese patients with type 2 diabetes mellitus: a cross-sectional study

• by Bo Huang, Yi-Rui Liang, Shi-Wei Li, Ya-Ning Li, Jing-Qiu Cui

• July 13, 2026